SCI's 21.5% Upside: UBS' $105 Call Exposes the Deathcare Rerating the Street May Still Be Missing

SCI looks like a rerating setup, but the spread across targets still matters

• Takeaway: SCI still sits below both analyst consensus at $100.33 and UBS' $105 target, so part of the near-term upside still depends on whether the higher targets gain traction.
• Bull case: Q2 results showed the business is still executing, with SCI delivering $0.90 EPS and $1.10 billion in revenue, while revenue increased 3.6% year over year.
• Bear case: Much of the Street remains clustered near $100.33, so the market may still be rewarding durability more than it is rewarding a full rerating.
• Watchlist: The key tension is whether operating momentum can hold if demand remains uneven.

UBS' upgrade matters because it came after a real operating beat

A bigger target was tied to live results

UBS did more than echo the quarter. It lifted its target from $93.00 to $105.00 after SCI posted $0.90 EPS and $1.10 billion in revenue, while revenue increased 3.6% year over year. That matters because the case was not built only on defensive demand or a generic stability narrative. The quarter gave the bull case harder evidence.

The market is still split, not settled

Other views remain less bullish. That keeps the debate alive: is SCI just a steady, defensive name, or does it deserve a richer multiple because it can still grow through pricing and mix? UBS is arguing for the latter. But until broader consensus moves farther in that direction, this looks more like an improving setup than a fully settled rerating.

Why the valuation case is more than a headline rerating

Scale gives the case more weight

SCI is large enough that investors can underwrite durability, not just defensibility. The company produced 2025 revenue of $4.31 billion and earnings were $542.61 million, an increase of 4.62%. That does not make it a high-growth story, but it does make a case for a better-quality multiple more credible.

This is also a platform business, not a single-brand story. SCI operates funeral service locations, cemeteries, funeral service/cemetery combination locations, crematoria, and other businesses across the United States and Canada. The point is not to overstate the appeal of the industry. It is to note that a broader footprint can give management more places to adjust pricing, improve mix, and absorb weaker local demand.

Why research tone matters more here

With 85.53% institutional ownership, SCI already looks like a core holding for many portfolios. In that kind of stock, shifts in analyst tone can matter because they reinforce or challenge an existing baseline view rather than create one from scratch.

Watch three things from here: - whether revenue growth stays positive, - whether earnings can continue to outgrow sales, and - whether research support remains constructive after the recent upgrade.

If those signals hold, UBS' call is less likely to be a one-quarter blip.

The main risk is still demand: better results do not remove volume pressure

Q2 improved the picture, but it did not erase the caution

Management previously warned that funeral volumes declined 6% in Q1. That is why the next few quarters matter so much. A stronger quarter can support confidence, but it does not prove that volume pressure is gone.

SCI still delivered $0.90 EPS and $1.10 billion in revenue, while revenue increased 3.6% year over year. That shows execution is holding up. What remains under scrutiny is how durable that execution is if demand cools again or pricing power weakens.

What changes the trade from here

If demand stays more stable, the spread between UBS' target and the rest of the Street can keep narrowing. If volume deteriorates again, investors are more likely to treat SCI as a steady compounder than as a fast rerating story.

That is the setup now: improved confidence, but still a market that needs repeated proof before fully changing how it values the company.